Neuronal death: where does the end begin?

Trends in Neurosciences

Volumn 30, Issue 4, 2007, Pages 159-166

  Conforti, Laura ^a   Adalbert, Robert ^a   Coleman, Michael P ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POLYGLUTAMINE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELLULAR DISTRIBUTION; GLAUCOMA; HUMAN; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFECT; REVIEW; SPINAL MUSCULAR ATROPHY;

ANIMALS; APOPTOSIS; DISEASE PROGRESSION; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 33947724269     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2007.02.004     Document Type: Review

References (80)

1. Miledi R., and Slater C.R. On the degeneration of rat neuromuscular junctions after nerve section. J. Physiol. 207 (1970) 507-528
2. Beirowski B., et al. The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves. BMC Neurosci. 6 (2005) 6
3. Koliatsos V.E., et al. Ventral root avulsion: an experimental model of death of adult motor neurons. J. Comp. Neurol. 342 (1994) 35-44
4. Beirowski B., et al. Quantitative and qualitative analysis of Wallerian degeneration using restricted axonal labelling in YFP-H mice. J. Neurosci. Methods 134 (2004) 23-35
5. Schaefer A.M., et al. A compensatory subpopulation of motor neurons in a mouse model of amyotrophic lateral sclerosis. J. Comp. Neurol. 490 (2005) 209-219
6. Pun S., et al. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 9 (2006) 408-419
7. s mutant and Ube4b/Nmnat transgenic mice. J. Physiol. 543 (2002) 739-755
8. Adalbert R., et al. The slow Wallerian degeneration gene in vivo protects motor axons but not their cell bodies after avulsion and neonatal axotomy. Eur. J. Neurosci. 24 (2006) 2163-2168
9. Libby R.T., et al. Susceptibility to neurodegeneration in glaucoma is modified by Bax gene dosage. PLoS Genet 1 (2005) 17-26
10. Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nat. Rev. Neurosci. 6 (2005) 889-898
11. Gillingwater T.H., et al. Delayed synaptic degeneration in the CNS of Wlds mice after cortical lesion. Brain 129 (2006) 1546-1556
12. Misgeld T., and Kerschensteiner M. In vivo imaging of the diseased nervous system. Nat. Rev. Neurosci. 7 (2006) 449-463
13. Helmchen F., and Denk W. Deep tissue two-photon microscopy. Nat. Methods 2 (2005) 932-940
14. Carrel T.L., et al. Survival motor neuron function in motor axons is independent of functions required for small nuclear ribonucleoprotein biogenesis. J. Neurosci. 26 (2006) 11014-11022
15. Kieran D., et al. A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J. Cell Biol. 169 (2005) 561-567
16. Stokin G.B., et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307 (2005) 1282-1288
17. Boillee S., et al. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52 (2006) 39-59
18. Martin N., et al. A missense mutation in Tbce causes progressive motor neuronopathy in mice. Nat. Genet. 32 (2002) 443-447
19. Hafezparast M., et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300 (2003) 808-812
20. Schmitt-John T., et al. Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat. Genet. 37 (2005) 1213-1215
21. Fischer L.R., et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185 (2004) 232-240
22. Gould T.W., et al. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J. Neurosci. 26 (2006) 8774-8786
23. Bendotti C., et al. Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J. Neurol. Sci. 191 (2001) 25-33
24. Martin L.J., et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J. Comp. Neurol. 500 (2006) 20-46
25. Veglianese P., et al. Activation of the p38MAPK cascade is associated with upregulation of TNFα receptors in the spinal motor neurons of mouse models of familial ALS. Mol. Cell. Neurosci. 31 (2006) 218-231
26. Raoul C., et al. Chronic activation in presymptomatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6007-6012
27. Ferri A., et al. Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr. Biol. 13 (2003) 669-673
28. Kostic V., et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277 (1997) 559-562
29. S gene modestly prolongs survival in the SOD1(G93A) fALS mouse. Neurobiol. Dis. 19 (2005) 293-300
30. McWhorter M.L., et al. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J. Cell Biol. 162 (2003) 919-931
31. Eggert C., et al. Spinal muscular atrophy: the RNP connection. Trends Mol. Med. 12 (2006) 113-121
32. Zhang H.L., et al. Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J. Neurosci. 23 (2003) 6627-6637
33. Rossoll W., et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of β-actin mRNA in growth cones of motoneurons. J. Cell Biol. 163 (2003) 801-812
34. Cifuentes-Diaz C., et al. Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Hum. Mol. Genet. 11 (2002) 1439-1447
35. Jablonka S., et al. Distinct and overlapping alterations in motor and sensory neurons in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 15 (2006) 511-518
36. Winkler C., et al. Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. Genes Dev. 19 (2005) 2320-2330
37. Martin K.R., et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4357-4365
38. Quigley H.A., et al. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch. Ophthalmol. 99 (1981) 635-649
39. May C.A., and Mittag T. Optic nerve degeneration in the DBA/2NNia mouse: is the lamina cribrosa important in the development of glaucomatous optic neuropathy?. Acta Neuropathol. (Berl.) 111 (2006) 158-167
40. Schlamp C.L., et al. Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric. BMC Neurosci. 7 (2006) 66
41. Pease M.E., et al. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 41 (2000) 764-774
42. Martin K.R., et al. Optic nerve dynein motor protein distribution changes with intraocular pressure elevation in a rat model of glaucoma. Exp. Eye Res. 83 (2006) 255-262
43. Jakobs T.C., et al. Retinal ganglion cell degeneration is topological but not cell type specific in DBA/2J mice. J. Cell Biol. 171 (2005) 313-325
44. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
45. Coleman P.D., and Yao P.J. Synaptic slaughter in Alzheimer's disease. Neurobiol. Aging 24 (2003) 1023-1027
46. Sheng J.G., et al. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Aβ amyloidosis. J. Neurosci. 22 (2002) 9794-9799
47. Adalbert, R. et al. (2007) Aβ, tau and ApoE4 in Alzheimer's disease: the axonal connection. Trends in Mol. Med. doi:10.1016/j.molmed.2007.02.004
48. Tsai J., et al. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat. Neurosci. 7 (2004) 1181-1183
49. Spires T.L., et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25 (2005) 7278-7287
50. Jacobsen J.S., et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5161-5166
51. Hsia A.Y., et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3228-3233
52. Polymeropoulos M.H., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
53. Martin L.J., et al. Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26 (2006) 41-50
54. Chandra S., et al. Alpha-synuclein cooperates with CSPα in preventing neurodegeneration. Cell 123 (2005) 383-396
55. Braak H., et al. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396 (2006) 67-72
56. Day M., et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 9 (2006) 251-259
57. s-mediated protection of dopaminergic fibers in an animal model of parkinson disease. Curr. Biol. 14 (2004) 326-330
58. S mice are protected against the Parkinsonian mimetic MPTP. Exp. Neurol. 202 (2006) 93-99
59. Vila M., et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2837-2842
60. Cattaneo E., et al. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6 (2005) 919-930
61. Benn C.L., et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum. Mol. Genet. 14 (2005) 3065-3078
62. DiProspero N.A., et al. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol. 33 (2004) 517-533
63. Yu Z.X., et al. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 23 (2003) 2193-2202
64. Murphy K.P., et al. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci. 20 (2000) 5115-5123
65. Li H., et al. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 21 (2001) 8473-8481
66. Schilling G., et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Hum. Mol. Genet. 13 (2004) 1599-1610
67. Iwata A., et al. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13135-13140
68. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443 (2006) 780-786
69. Arrasate M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
70. Arango M., et al. CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. J. Neurosci. 26 (2006) 4649-4659
71. Parker J.A., et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 37 (2005) 349-350
72. Zhai W., et al. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 123 (2005) 1241-1253
73. Katsuno M., et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J. Neurosci. 26 (2006) 12106-12117
74. Gunawardena S., et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40 (2003) 25-40
75. Morfini G., et al. Polyglutamine expansion diseases: failing to deliver. Trends Mol. Med. 11 (2005) 64-70
76. Cunningham C., et al. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 25 (2005) 9275-9284
77. Macdonald J.M., et al. The Drosophila cell corpse engulfment receptor draper mediates glial clearance of severed axons. Neuron 50 (2006) 869-881
78. s protection distinguishes axon degeneration following injury from naturally occurring developmental pruning. Neuron 50 (2006) 883-895
79. Driscoll M., and Gerstbrein B. Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat. Rev. Genet. 4 (2003) 181-194
80. Schmalbruch H., et al. A new mouse mutant with progressive motor neuronopathy. J. Neuropathol. Exp. Neurol. 50 (1991) 192-204